For small and mid-sized enterprises (SMEs), clinical trials for new drugs or medical devices are an essential development step, but the enormous costs—combined with limited funding and manpower—pose a major hurdle. In South Korea, companies must meet the strict requirements of the Ministry of Food and Drug Safety (MFDS), and unexpected expenses often arise during trial preparation.
In response, many companies are turning to Korean CROs (Contract Research Organizations) as key partners to overcome these challenges. Even resource-constrained startups and biotech ventures are collaborating with CROs to drive efficient clinical development with limited resources. Global pharmaceutical companies, too, are increasingly outsourcing clinical trials to CROs to reduce R&D costs. Below, we explore 5 ways to reduce clinical trial costs and streamline the MFDS approval process by leveraging CRO support.
1. Reducing Unnecessary Trial Phases with CRO Collaboration
Unlike large companies, SMEs without ample resources must eliminate inefficiencies in the clinical trial process to survive. In medical device trials, the process is generally divided into exploratory trials and confirmatory trials, with exploratory trials aimed at validating the study design and gathering preliminary data. However, if exploratory studies are repeated without a clear strategy or if inappropriate endpoints are set, a company may fail to collect enough data for the confirmatory trial, causing delays in the overall timeline. An experienced CRO can establish a strategy to shrink or integrate exploratory trial phases by leveraging literature on similar devices, past MFDS approval cases, and existing research results.
For example, one Korean startup developing a wearable biosensor was advised by its CRO to combine the usability testing and safety evaluation in the exploratory stage. This integration saved about 3 months of time and roughly KRW 20 million (approximately USD 15,000) in costs. Moreover, from the early design phase, the CRO helped identify statistically significant endpoints and determine the appropriate number of subjects, enabling a seamless transition to the confirmatory trial.
2. Proactively Meeting MFDS Requirements with an Expert CRO
The MFDS approval process for medical devices is highly complex. Devices are classified from Class I to Class IV, and especially for Class III and IV high-risk devices, at least 10 different documents (such as biocompatibility test reports, clinical trial result reports, and manufacturing process validation data) must be submitted. If an SME attempts to prepare all these materials in-house, it would need to hire legal experts, data analysts, clinical specialists, etc., making costly trial-and-error mistakes more likely.
In contrast, a specialized CRO is well-versed in the latest MFDS guidelines (as of 2024, for example the Medical Device Clinical Trial Management Standards) and can systematically manage the entire process from protocol development and data collection to statistical analysis. For example, a CRO can monitor adverse event data in real time during the trial and organize it in the MFDS-required format, greatly reducing the time needed to prepare regulatory submissions. In one case, an SME that engaged a CRO cut the preparation and review period for required approval documents from 6 months to 3 months. This minimized the trial-and-error stemming from their lack of in-house regulatory staff, saving about KRW 20 million in labor and consulting fees. Such proactive preparation by the CRO helped prevent unnecessary expenditures during the drug and device approval process.
3. Leveraging CRO Networks to Maximize External Resources
For an SME to build its own clinical trial infrastructure, the upfront investment can reach several hundred million KRW (hundreds of thousands of USD) for costly equipment and specialized facilities. A CRO’s extensive network can significantly reduce these startup costs. CROs maintain links with university hospital clinical trial centers, certified clinical research institutions, and skilled research personnel, and can connect your project to the right external resources as needed.
For example, one company was able to obtain high-quality data at a university hospital’s clinical trial center without building its own facility by working through a CRO. In this process, instead of spending hundreds of millions of won to purchase equipment, they paid only about KRW 5 million (around USD 4,000) per month to rent it—achieving roughly a 40% reduction in upfront costs. Additionally, CROs often assist in negotiations with hospitals to adjust trial execution fees, frequently securing extra discounts or favorable collaboration terms. Especially for expensive studies like large-scale, multi-center oncology trials (which require extensive patient enrollment and long durations), leveraging a CRO’s network to improve efficiency is essential.
4. Preventing Rework through Data Management Expertise
Errors or omissions in clinical trial data can be devastating for an SME. The MFDS enforces strict data integrity requirements for drug and device approvals; if an error is found, regulators might re-examine the entire trial or demand additional experiments, doubling the costs and causing significant delays. A CRO employs advanced tools like Electronic Data Capture (EDC) systems to verify data accuracy in real time, and a dedicated biostatistics team to analyze results—catching errors early before they snowball into bigger problems.
One SME, for instance, faced the prospect of a repeat trial costing around KRW 20 million (~USD 15,000) due to data entry errors in a self-run study. After switching to a CRO mid-study, the error rate dropped by over 90%, allowing the company to avoid those additional costs. Furthermore, a CRO can immediately generate MFDS-ready final reports as soon as a trial ends, minimizing any separate data compilation or rework and thus saving time and money.
5. One Clinical Trial for Multiple Market Approvals
If an SME wants to expand beyond Korea into global markets, its clinical trial data must comply with international standards (such as ISO 14155 and ICH-GCP guidelines). However, preparing separately for overseas regulatory approvals—on top of domestic approval—requires additional multinational regulatory knowledge and specialized personnel, causing costs to skyrocket. Working with an experienced CRO makes it possible to devise a strategy that addresses both domestic and international regulatory requirements in a single trial.
For example, one Korean startup, with the help of a CRO, conducted a clinical trial that met MFDS approval requirements while simultaneously collecting the data needed for a European CE Mark and U.S. FDA approval. This approach saved an estimated KRW 30 million (about USD 25,000) in additional costs that would have been spent on separate overseas trials. In short, leveraging a Korean CRO’s global clinical experience allows one trial to satisfy multiple regulators’ requirements, saving significant time and expense. In fields like oncology drug development, where global multi-center trials are mandatory, using a Korean CRO is especially invaluable. They ensure that documentation and data management are aligned with international standards, which increases the likelihood that data from a domestic trial will be accepted by regulators in other countries.
Achieve Cost Savings and Success with Intoinworld
In summary, while clinical trials present continuous costs and risks for SMEs, partnering with a CRO offers the following key advantages:
- Eliminating unnecessary trial stages to save time and budget
- Effectively addressing MFDS and other regulatory requirements to prevent approval delays
- Leveraging external hospital/institute networks to minimize facility investment costs
- Utilizing professional data management to avoid repeat trials and extra work
- Preparing for multiple market approvals with a single trial
So why choose Intoinworld among the many CRO options? Intoinworld is a Korea-based CRO with over 10 years of experience and deep expertise in the Asian market, offering customized services for SMEs. It boasts a high success rate in MFDS approvals and has achieved an average of 25% cost reduction for its clients. Additionally, Intoinworld’s multilingual support team and global partner network enable seamless support for trials not only in Korea but also in the US, Europe, and other regions. By partnering with Intoinworld, companies can attain both significant cost savings and a successful regulatory approval outcome at the same time.
If you are looking for ways to reduce clinical trial costs, we encourage you to request a quote from Intoinworld to receive a tailored consultation. And if you don’t want to miss the latest pharma/biotech industry trends and clinical trial insights, consider subscribing to Intoinworld’s newsletter to get valuable information on a regular basis.
Frequently Asked Questions (FAQ)
Q1. If I outsource to a CRO, won’t the fees end up making it more expensive?
A. On the surface, the fees paid to a CRO might seem like an extra expense. However, when you consider the entire process, using a CRO is often more cost-effective. Managing a clinical trial in-house can incur hidden costs due to inexperience—such as costly trial-and-error, timeline delays, or even repeat trials because of errors. In contrast, a CRO’s expertise and streamlined processes help minimize these pitfalls, saving considerable time and personnel costs. In fact, pharmaceutical companies are increasingly outsourcing trials to CROs as a way to reduce R&D expenses. While hiring a CRO adds an upfront fee, from a whole-project perspective it prevents unnecessary spending and ultimately lowers the total cost.
Q2. What are the advantages of choosing a Korean CRO over a large global CRO?
A. A Korean CRO is an optimal partner for the local regulatory environment and clinical landscape. There are no language or cultural barriers, and no time-zone gaps, which means communication is smooth and close collaboration is possible. Particularly, Korean CROs have a precise understanding of MFDS procedures and requirements for drug and medical device approvals, giving them an edge in speed and accuracy when navigating domestic regulations. Also, in terms of cost, CROs based in Korea often offer more reasonable pricing structures. A Korean CRO like Intoinworld brings a deep understanding and network within the Asian market, which is advantageous when expanding to other Asian countries using data from Korean trials. By contrast, global CROs do have extensive worldwide networks, but they often charge higher fees and may be less flexible due to rigid standardized processes. In summary, a Korean CRO provides both local expertise and cost efficiency.
Q3. Can a Korean CRO help prepare for FDA or EMA approval as well?
A. Yes. A seasoned Korean CRO will design and conduct domestic trials in accordance with international standards (such as ICH-GCP), meaning the data can be used in submissions to regulators like the U.S. FDA or the European Medicines Agency (EMA). An experienced CRO – such as Intoinworld – can even help you prepare for global approvals in one go by producing reports tailored to FDA/EMA requirements and advising on any additional study design needs. Just be sure to clearly communicate your target markets (e.g. the US or Europe) early in the planning process so the CRO can design the protocol to meet those specific regulatory requirements. In fact, Intoinworld has previously structured domestic trials to simultaneously gather data for overseas approvals, thereby saving the cost of separate foreign trials. With the right coordination, leveraging a Korean CRO to link domestic trial results to FDA/EMA approvals is a very feasible strategy.